Multiparametric magnetic resonance imaging and magnetic resonance imaging fusion-guided biopsy for the diagnosis of prostate cancer: current status

Abstract

This review explains the role of multiparametric magnetic resonance imaging, particularly in prostate biopsy, in the detection of prostate cancer. The use of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer has also allowed its use in magnetic resonance imaging-guided biopsies, which according to many studies present high sensitivity and specificity in early diagnosis and staging, in patients with persistently high prostate-specific antigen levels despite previous negative prostate biopsies, and in the follow-up of patients under active surveillance.

To perform a targeted prostate biopsy, three types of magnetic resonance imaging guidance are available: cognitive fusion, direct magnetic resonance imaging-guided biopsy performed within a tomograph (in-bore biopsies), and software coregistration of stored magnetic resonance images with real-time ultrasound using a fusion device, with multiparametric magnetic resonance imaging findings digitally overlaid on real-time transrectal ultrasound images for targeted biopsy.

Each method has its advantages and disadvantages. Magnetic resonance imaging-targeted biopsy improves the quality of histological results compared with other approaches, with approximately 90% correct detection of significant index lesions. Correct staging allows the selection of the best therapeutic options, adequate evaluation of the prognosis, and reduction of the incidence of new biopsies and complications. The current objective is to make magnetic resonance imaging-guided biopsy increasingly available and standardize the technique to minimize inter-operator variability depending on the available system.

Keywords

multiparametric magnetic resonance imaging / prostate cancer / fusion biopsy / targeted biopsy

References

[1] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–629. doi: 10.1016/j.eururo.2016.08.003

[2] Mottet N., Bellmunt J., Bolla M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2017. Vol. 71, N 4. P. 618–629. doi: 10.1016/j.eururo.2016.08.003

[3] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–629. doi: 10.1016/j.eururo.2016.08.003

[4] Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713–719. doi: 10.1016/j.eururo.2013.05.059

[5] Siddiqui M.M., Rais-Bahrami S., Truong H., et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy // Eur Urol. 2013. Vol. 64, N 5. P. 713–719. doi: 10.1016/j.eururo.2013.05.059

[6] Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713–719. doi: 10.1016/j.eururo.2013.05.059

[7] Bjurlin MA, Meng X, Le Nobin J, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648–658. doi: 10.1016/j.juro.2014.03.117

[8] Bjurlin M.A., Meng X., Le Nobin J., et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment // J Urol. 2014. Vol. 192, N 3. P. 648–658. doi: 10.1016/j.juro.2014.03.117

[9] Bjurlin MA, Meng X, Le Nobin J, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648–658. doi: 10.1016/j.juro.2014.03.117

[10] [WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK: Public Health England; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks

[11] [WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK : Public Health England, 2016. Доступ по ссылке: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks

[12] [WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK: Public Health England; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks

[13] Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. 2015;67(6):1112–1121. doi: 10.1016/j.eururo.2014.10.033

[14] Hamoen E.H.J., de Rooij M., Witjes J.A., Barentsz J.O., Rovers M.M. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis // Eur Urol. 2015. Vol. 67, N 6. P. 1112–1121. doi: 10.1016/j.eururo.2014.10.033

[15] Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. 2015;67(6):1112–1121. doi: 10.1016/j.eururo.2014.10.033

[16] Ventrella E, Eusebi L, Carpagnano FA, et al. Multiparametric MRI of Prostate Cancer: Recent Advances. Curr Radiol Rep. 2020;8. doi: 10.1007/s40134-020-00363-1

[17] Ventrella E., Eusebi L., Carpagnano F.A., et al. Multiparametric MRI of Prostate Cancer: Recent Advances // Curr Radiol Rep. 2020. Vol. 8. doi: 10.1007/s40134-020-00363-1

[18] Ventrella E, Eusebi L, Carpagnano FA, et al. Multiparametric MRI of Prostate Cancer: Recent Advances. Curr Radiol Rep. 2020;8. doi: 10.1007/s40134-020-00363-1

[19] Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62(6):986–996. doi: 10.1016/j.eururo.2012.06.044

[20] Portalez D., Mozer P., Cornud F., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients // Eur Urol. 2012. Vol. 62, N 6. P. 986–996. doi: 10.1016/j.eururo.2012.06.044

[21] Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62(6):986–996. doi: 10.1016/j.eururo.2012.06.044

[22] Kuru TH, Roethke MC, Rieker P, et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112(8):1080–1087. doi: 10.1111/bju.12259

[23] Kuru T.H., Roethke M.C., Rieker P., et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate // BJU Int. 2013. Vol. 112, N 8. P. 1080–1087. doi: 10.1111/bju.12259

[24] Kuru TH, Roethke MC, Rieker P, et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112(8):1080–1087. doi: 10.1111/bju.12259

[25] Carpagnano F, Eusebi L, Tupputi U, et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020;8. doi: 10.1007/s40134-020-00374-y

[26] Carpagnano F., Eusebi L., Tupputi U., et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020. Vol. 8. doi: 10.1007/s40134-020-00374-y

[27] Carpagnano F, Eusebi L, Tupputi U, et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020;8. doi: 10.1007/s40134-020-00374-y

[28] Arsov C, Rabenalt R, Blondin D, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68(4):713–720. doi: 10.1016/j.eururo.2015.06.008

[29] Arsov C., Rabenalt R., Blondin D., et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies // Eur Urol. 2015. Vol. 68, N 4. P. 713–720. doi: 10.1016/j.eururo.2015.06.008

[30] Arsov C, Rabenalt R, Blondin D, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68(4):713–720. doi: 10.1016/j.eururo.2015.06.008

[31] Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520–527. doi: 10.1016/j.juro.2009.10.022

[32] Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen // J Urol. 2010. Vol. 183, N 2. P. 520–527. doi: 10.1016/j.juro.2009.10.022

[33] Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520–527. doi: 10.1016/j.juro.2009.10.022

[34] Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol. 2016;34(7):326–332. doi: 10.1016/j.urolonc.2016.03.005

[35] Tyson M.D., Arora S.S., Scarpato K.R., Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer // Urol Oncol. 2016. Vol. 34, N 7. P. 326–332. doi: 10.1016/j.urolonc.2016.03.005

[36] Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol. 2016;34(7):326–332. doi: 10.1016/j.urolonc.2016.03.005

[37] Wolters T, Montironi R, Mazzucchelli R, et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate. 2012;72(1):108–115. doi: 10.1002/pros.21415

[38] Wolters T., Montironi R., Mazzucchelli R., et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy // Prostate. 2012. Vol. 72, N 1. P. 108–115. doi: 10.1002/pros.21415

[39] Wolters T, Montironi R, Mazzucchelli R, et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate. 2012;72(1):108–115. doi: 10.1002/pros.21415

[40] Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140. doi: 10.1016/j.eururo.2012.06.004

[41] Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review // Eur Urol. 2013. Vol. 63, N 1. P. 125–140. doi: 10.1016/j.eururo.2012.06.004

[42] Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140. doi: 10.1016/j.eururo.2012.06.004

[43] Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology. 2013;268(2):461–469. doi: 10.1148/radiol.13121501

[44] Puech P., Rouvière O., Renard-Penna R., et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study // Radiology. 2013. Vol. 268, N 2. P. 461–469. doi: 10.1148/radiol.13121501

[45] Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology. 2013;268(2):461–469. doi: 10.1148/radiol.13121501

[46] Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis. 2010;13(1):65–70. doi: 10.1038/pcan.2009.41

[47] Labanaris A.P., Engelhard K., Zugor V., Nützel R., Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate // Prostate Cancer Prostatic Dis. 2010. Vol. 13, N 1. P. 65–70. doi: 10.1038/pcan.2009.41

[48] Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis. 2010;13(1):65–70. doi: 10.1038/pcan.2009.41

[49] Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217(8):424–433. doi: 10.5694/mja2.51722

[50] Williams I.S., McVey A., Perera S., et al. Modern paradigms for prostate cancer detection and management // Med J Aust. 2022. Vol. 217, N 8. P. 424–433. doi: 10.5694/mja2.51722

[51] Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217(8):424–433. doi: 10.5694/mja2.51722

[52] Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108(8 Pt 2):E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x

[53] Haffner J., Lemaitre L., Puech P., et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection // BJU Int. 2011. Vol. 108, N 8 Pt 2. P. E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x

[54] Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108(8 Pt 2):E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x

[55] Labanaris AP, Zugor V, Smiszek R, et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magn Reson Imaging. 2010;28(7):943–946. doi: 10.1016/j.mri.2010.03.041

[56] Labanaris A.P., Zugor V., Smiszek R., et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology // Magn Reson Imaging. 2010. Vol. 28, N 7. P. 943–946. doi: 10.1016/j.mri.2010.03.041

[57] Labanaris AP, Zugor V, Smiszek R, et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magn Reson Imaging. 2010;28(7):943–946. doi: 10.1016/j.mri.2010.03.041

[58] Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014;41(2):315–326. doi: 10.1016/j.ucl.2014.01.007

[59] Stephenson S.K., Chang E.K., Marks L.S. Screening and detection advances in magnetic resonance image-guided prostate biopsy // Urol Clin North Am. 2014. Vol. 41, N 2. P. 315–326. doi: 10.1016/j.ucl.2014.01.007

[60] Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014;41(2):315–326. doi: 10.1016/j.ucl.2014.01.007

[61] Vourganti S, Rastinehad A, Yerram N, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–2157. doi: 10.1016/j.juro.2012.08.025

[62] Vourganti S., Rastinehad A., Yerram N., et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies // J Urol. 2012. Vol. 188, N 6. P. 2152–2157. doi: 10.1016/j.juro.2012.08.025

[63] Vourganti S, Rastinehad A, Yerram N, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–2157. doi: 10.1016/j.juro.2012.08.025

[64] Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–397. doi: 10.1001/jama.2014.17942

[65] Siddiqui M.M., Rais-Bahrami S., Turkbey B., et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer // JAMA. 2015. Vol. 313, N 4. P. 390–397. doi: 10.1001/jama.2014.17942

[66] Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–397. doi: 10.1001/jama.2014.17942

[67] Quentin M, Schimmöller L, Arsov C, et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. Acta Radiol. 2013;54(10):1224–1229. doi: 10.1177/0284185113492972

[68] Quentin M., Schimmöller L., Arsov C., et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization // Acta Radiol. 2013. Vol. 54, N 10. P. 1224–1229. doi: 10.1177/0284185113492972

[69] Quentin M, Schimmöller L, Arsov C, et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. Acta Radiol. 2013;54(10):1224–1229. doi: 10.1177/0284185113492972

[70] Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902–909. doi: 10.1016/j.eururo.2012.01.047

[71] Hoeks C.M., Schouten M.G., Bomers J.G., et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers // Eur Urol. 2012. Vol. 62, N 5. P. 902–909. doi: 10.1016/j.eururo.2012.01.047

[72] Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902–909. doi: 10.1016/j.eururo.2012.01.047

[73] Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013;23(1):43–50. doi: 10.1097/MOU.0b013e32835ad3ee

[74] Marks L., Young S., Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy // Curr Opin Urol. 2013. Vol. 23, N 1. P. 43–50. doi: 10.1097/MOU.0b013e32835ad3ee

[75] Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013;23(1):43–50. doi: 10.1097/MOU.0b013e32835ad3ee

[76] Monni F, Fontanella P, Grasso A, et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urol Nefrol. 2017;69(6):567–578. doi: 10.23736/S0393-2249.17.02819-3

[77] Monni F., Fontanella P., Grasso A., et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review // Minerva Urol Nefrol. 2017. Vol. 69, N 6. P. 567–578. doi: 10.23736/S0393-2249.17.02819-3

[78] Monni F, Fontanella P, Grasso A, et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urol Nefrol. 2017;69(6):567–578. doi: 10.23736/S0393-2249.17.02819-3

[79] Schlaier JR, Warnat J, Dorenbeck U, et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system. Acta Neurochir (Wien). 2004;146(3):271–276. doi: 10.1007/s00701-003-0155-6

[80] Schlaier J.R., Warnat J., Dorenbeck U., et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system // Acta Neurochir (Wien). 2004. Vol. 146, N 3. P. 271–276. doi: 10.1007/s00701-003-0155-6

[81] Schlaier JR, Warnat J, Dorenbeck U, et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system. Acta Neurochir (Wien). 2004;146(3):271–276. doi: 10.1007/s00701-003-0155-6

[82] Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66(1):22–29. doi: 10.1016/j.eururo.2014.03.002

[83] Pokorny M.R., de Rooij M., Duncan E., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies // Eur Urol. 2014. Vol. 66, N 1. P. 22–29. doi: 10.1016/j.eururo.2014.03.002

[84] Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66(1):22–29. doi: 10.1016/j.eururo.2014.03.002

[85] Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190(4):1380–1386. doi: 10.1016/j.juro.2013.04.043

[86] Kuru T.H., Roethke M.C., Seidenader J., et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer // J Urol. 2013. Vol. 190, N 4. P. 1380–1386. doi: 10.1016/j.juro.2013.04.043

[87] Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190(4):1380–1386. doi: 10.1016/j.juro.2013.04.043

[88] Serefoglu EC, Altinova S, Ugras NS, et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer. Can Urol Assoc J. 2013;7(5-6):E293–E298. doi: 10.5489/cuaj.11224

[89] Serefoglu E.C., Altinova S., Ugras N.S., et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? // Can Urol Assoc J. 2013. Vol. 7, N 5-6. P. E293–E298. doi: 10.5489/cuaj.11224

[90] Serefoglu EC, Altinova S, Ugras NS, et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer. Can Urol Assoc J. 2013;7(5-6):E293–E298. doi: 10.5489/cuaj.11224

[91] Baco E, Ukimura O, Rud E, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2015;67(4):787–794. doi: 10.1016/j.eururo.2014.08.077

[92] Baco E., Ukimura O., Rud E., et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients // Eur Urol. 2015. Vol. 67, N 4. P. 787–794. doi: 10.1016/j.eururo.2014.08.077

[93] Baco E, Ukimura O, Rud E, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2015;67(4):787–794. doi: 10.1016/j.eururo.2014.08.077

[94] Cerantola Y, Dragomir A, Tanguay S, et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. Urol Oncol. 2016;34(3):119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010

[95] Cerantola Y., Dragomir A., Tanguay S., et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer // Urol Oncol. 2016. Vol. 34, N 3. P. 119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010

[96] Cerantola Y, Dragomir A, Tanguay S, et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. Urol Oncol. 2016;34(3):119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010

[97] Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol. 2013;189(2):493–499. doi: 10.1016/j.juro.2012.08.195

[98] Delongchamps N.B., Peyromaure M., Schull A., et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies // J Urol. 2013. Vol. 189, N 2. P. 493–499. doi: 10.1016/j.juro.2012.08.195

[99] Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol. 2013;189(2):493–499. doi: 10.1016/j.juro.2012.08.195

[100] Bax J, Cool D, Gardi L, et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys. 2008;35(12):5397–5410. doi: 10.1118/1.3002415

[101] Bax J., Cool D., Gardi L., et al. Mechanically assisted 3D ultrasound guided prostate biopsy system // Med Phys. 2008. Vol. 35, N 12. P. 5397–5410. doi: 10.1118/1.3002415

[102] Bax J, Cool D, Gardi L, et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys. 2008;35(12):5397–5410. doi: 10.1118/1.3002415

[103] US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913. Erratum in: JAMA. 2018;319(23):2443. doi: 10.1001/jama.2018.3710

[104] US Preventive Services Task Force; Grossman D.C., Curry S.J., et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement // JAMA. 2018. Vol. 319, N 18. P. 1901–1913. Erratum in: JAMA. 2018. Vol. 319, N 23. P. 2443. doi: 10.1001/jama.2018.3710

[105] US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913. Erratum in: JAMA. 2018;319(23):2443. doi: 10.1001/jama.2018.3710

[106] Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–360. doi: 10.1016/j.eururo.2014.12.006

[107] Arnsrud Godtman R., Holmberg E., Lilja H., Stranne J., Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial // Eur Urol. 2015. Vol. 68, N 3. P. 354–360. doi: 10.1016/j.eururo.2014.12.006

[108] Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–360. doi: 10.1016/j.eururo.2014.12.006

[109] Engler J, Dahlhaus A, Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey. Eur J Gen Pract. 2017;23(1):11–19. doi: 10.1080/13814788.2016.1240166

[110] Engler J., Dahlhaus A., Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey // Eur J Gen Pract. 2017. Vol. 23, N 1. P. 11–19. doi: 10.1080/13814788.2016.1240166

[111] Engler J, Dahlhaus A, Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey. Eur J Gen Pract. 2017;23(1):11–19. doi: 10.1080/13814788.2016.1240166

[112] Nordström T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–425. doi: 10.1016/j.eururo.2012.10.001

[113] Nordström T., Aly M., Clements M.S., et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011 // Eur Urol. 2013. Vol. 63, N 3. P. 419–425. doi: 10.1016/j.eururo.2012.10.001

[114] Nordström T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–425. doi: 10.1016/j.eururo.2012.10.001

[115] Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80(6):703–711. doi: 10.1016/j.eururo.2021.07.024

[116] Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021 // Eur Urol. 2021. Vol. 80, N 6. P. 703–711. doi: 10.1016/j.eururo.2021.07.024

[117] Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80(6):703–711. doi: 10.1016/j.eururo.2021.07.024

[118] Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042

[119] Mottet N., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2021. Vol. 79, N 2. P. 243–262. doi: 10.1016/j.eururo.2020.09.042

[120] Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042

[121] Collen S, Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe. Belg J Med Oncol. 2020;14:321–326.

[122] Collen S., Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe // Belg J Med Oncol. 2020. Vol. 14. P. 321–326.

[123] Collen S, Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe. Belg J Med Oncol. 2020;14:321–326.

[124] Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848–864. doi: 10.1093/annonc/mdu525

[125] Louie K.S., Seigneurin A., Cathcart P., Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis // Ann Oncol. 2015. Vol. 26, N 5. P. 848–864. doi: 10.1093/annonc/mdu525

[126] Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848–864. doi: 10.1093/annonc/mdu525

[127] Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi: 10.1016/S0140-6736(16)32401-1

[128] Ahmed H.U., El-Shater Bosaily A., Brown L.C., et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study // Lancet. 2017. Vol. 389, N 10071. P. 815–822. doi: 10.1016/S0140-6736(16)32401-1

[129] Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi: 10.1016/S0140-6736(16)32401-1

[130] Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging. Eur Urol. 2018;73(3):343–350. doi: 10.1016/j.eururo.2017.06.019

[131] Alberts A.R., Schoots I.G., Bokhorst L.P., et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? // Eur Urol. 2018. Vol. 73, N 3. P. 343–350. doi: 10.1016/j.eururo.2017.06.019

[132] Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging. Eur Urol. 2018;73(3):343–350. doi: 10.1016/j.eururo.2017.06.019

[133] Palsdottir T, Nordstrom T, Karlsson A, et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open. 2019;9(3):e027958. doi: 10.1136/bmjopen-2018-027958

[134] Palsdottir T., Nordstrom T., Karlsson A., et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study // BMJ Open. 2019. Vol. 9, N 3. P. e027958. doi: 10.1136/bmjopen-2018-027958

[135] Palsdottir T, Nordstrom T, Karlsson A, et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open. 2019;9(3):e027958. doi: 10.1136/bmjopen-2018-027958

[136] Wynants L, van Smeden M, McLernon DJ, et al. Three myths about risk thresholds for prediction models. BMC Med. 2019;17(1):192. doi: 10.1186/s12916-019-1425-3

[137] Wynants L., van Smeden M., McLernon D.J., et al. Three myths about risk thresholds for prediction models // BMC Med. 2019. Vol. 17, N 1. P. 192. doi: 10.1186/s12916-019-1425-3

[138] Wynants L, van Smeden M, McLernon DJ, et al. Three myths about risk thresholds for prediction models. BMC Med. 2019;17(1):192. doi: 10.1186/s12916-019-1425-3

[139] Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014;32(6):903–911. doi: 10.1016/j.urolonc.2013.08.006

[140] Sonn G.A., Margolis D.J., Marks L.S. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy // Urol Oncol. 2014. Vol. 32, N 6. P. 903–911. doi: 10.1016/j.urolonc.2013.08.006

[141] Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014;32(6):903–911. doi: 10.1016/j.urolonc.2013.08.006

[142] Sonn GA, Natarajan S, Margolis DJ, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86–91. doi: 10.1016/j.juro.2012.08.095

[143] Sonn G.A., Natarajan S., Margolis D.J., et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device // J Urol. 2013. Vol. 189, N 1. P. 86–91. doi: 10.1016/j.juro.2012.08.095

[144] Sonn GA, Natarajan S, Margolis DJ, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86–91. doi: 10.1016/j.juro.2012.08.095

[145] Robertson NL, Hu Y, Ahmed HU, et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. Eur Urol. 2014;65(3):628–634. doi: 10.1016/j.eururo.2012.12.057

[146] Robertson N.L., Hu Y., Ahmed H.U., et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study // Eur Urol. 2014. Vol. 65, N 3. P. 628–634. doi: 10.1016/j.eururo.2012.12.057

[147] Robertson NL, Hu Y, Ahmed HU, et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. Eur Urol. 2014;65(3):628–634. doi: 10.1016/j.eururo.2012.12.057

[148] Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–853. doi: 10.1016/j.eururo.2015.12.052

[149] Radtke J.P., Schwab C., Wolf M.B., et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen // Eur Urol. 2016. Vol. 70. P. 846–853. doi: 10.1016/j.eururo.2015.12.052

[150] Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–853. doi: 10.1016/j.eururo.2015.12.052

[151] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi: 10.1016/S0140-6736(14)60525-0

[152] Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up // Lancet. 2014. Vol. 384, N 9959. P. 2027–2035. doi: 10.1016/S0140-6736(14)60525-0

[153] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi: 10.1016/S0140-6736(14)60525-0

[154] Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85. doi: 10.1016/j.eururo.2009.08.025

[155] Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer // Eur Urol. 2010. Vol. 57, N 1. P. 79–85. doi: 10.1016/j.eururo.2009.08.025

[156] Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85. doi: 10.1016/j.eururo.2009.08.025

[157] Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512–517. doi: 10.1016/j.eururo.2015.06.005

[158] Meng X., Rosenkrantz A.B., Mendhiratta N., et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes // Eur Urol. 2016. Vol. 69, N 3. P. 512–517. doi: 10.1016/j.eururo.2015.06.005

[159] Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512–517. doi: 10.1016/j.eururo.2015.06.005

[160] Vargas HA, Hötker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. 2016;26(6):1606–1612. doi: 10.1007/s00330-015-4015-6

[161] Vargas H.A., Hötker A.M., Goldman D.A., et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference // Eur Radiol. 2016. Vol. 26, N 6. P. 1606–1612. doi: 10.1007/s00330-015-4015-6

[162] Vargas HA, Hötker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. 2016;26(6):1606–1612. doi: 10.1007/s00330-015-4015-6

[163] Radtke JP, Wiesenfarth M, Kesch C, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017;72(6):888–896. doi: 10.1016/j.eururo.2017.03.039

[164] Radtke J.P., Wiesenfarth M., Kesch C., et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies // Eur Urol. 2017. Vol. 72, N 6. P. 888–896. doi: 10.1016/j.eururo.2017.03.039

[165] Radtke JP, Wiesenfarth M, Kesch C, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017;72(6):888–896. doi: 10.1016/j.eururo.2017.03.039

[166] van Leeuwen PJ, Hayen A, Thompson JE, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017;120(6):774–781. doi: 10.1111/bju.13814

[167] van Leeuwen P.J., Hayen A., Thompson J.E., et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy // BJU Int. 2017. Vol. 120, N 6. P. 774–781. doi: 10.1111/bju.13814

[168] van Leeuwen PJ, Hayen A, Thompson JE, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017;120(6):774–781. doi: 10.1111/bju.13814

[169] Muthigi A, George AK, Sidana A, et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. J Urol. 2017;197(2):327–334. doi: 10.1016/j.juro.2016.08.097

[170] Muthigi A., George A.K., Sidana A., et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy // J Urol. 2017. Vol. 197, N 2. P. 327–334. doi: 10.1016/j.juro.2016.08.097

[171] Muthigi A, George AK, Sidana A, et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. J Urol. 2017;197(2):327–334. doi: 10.1016/j.juro.2016.08.097

[172] Cash H, Günzel K, Maxeiner A, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118(1):35–43. doi: 10.1111/bju.13327

[173] Cash H., Günzel K., Maxeiner A., et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure // BJU Int. 2016. Vol. 118, N 1. P. 35–43. doi: 10.1111/bju.13327

[174] Cash H, Günzel K, Maxeiner A, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118(1):35–43. doi: 10.1111/bju.13327

[175] Bryk DJ, Llukani E, Taneja SS, et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017;102:178–182. doi: 10.1016/j.urology.2016.11.017

[176] Bryk D.J., Llukani E., Taneja S.S., et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy // Urology. 2017. Vol. 102. P. 178–182. doi: 10.1016/j.urology.2016.11.017

[177] Bryk DJ, Llukani E, Taneja SS, et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017;102:178–182. doi: 10.1016/j.urology.2016.11.017

[178] Porpiglia F, De Luca S, Passera R, et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. J Urol. 2017;198(1):58–64. doi: 10.1016/j.juro.2017.01.036

[179] Porpiglia F., De Luca S., Passera R., et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization // J Urol. 2017. Vol. 198, N 1. P. 58–64. doi: 10.1016/j.juro.2017.01.036

[180] Porpiglia F, De Luca S, Passera R, et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. J Urol. 2017;198(1):58–64. doi: 10.1016/j.juro.2017.01.036

[181] Fütterer JJ, Briganti A, De Visschere P, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015;68(6):1045–1053. doi: 10.1016/j.eururo.2015.01.013

[182] Fütterer J.J., Briganti A., De Visschere P., et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature // Eur Urol. 2015. Vol. 68, N 6. P. 1045–1053. doi: 10.1016/j.eururo.2015.01.013

[183] Fütterer JJ, Briganti A, De Visschere P, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015;68(6):1045–1053. doi: 10.1016/j.eururo.2015.01.013

[184] Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192(1):67–74. doi: 10.1016/j.juro.2014.01.014

[185] Thompson J.E., Moses D., Shnier R., et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study // J Urol. 2014. Vol. 192, N 1. P. 67–74. doi: 10.1016/j.juro.2014.01.014

[186] Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192(1):67–74. doi: 10.1016/j.juro.2014.01.014

[187] Delongchamps NB, Portalez D, Bruguière E, et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer. J Urol. 2016;196(4):1069–1075. doi: 10.1016/j.juro.2016.04.003

[188] Delongchamps N.B., Portalez D., Bruguière E., et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer? // J Urol. 2016. Vol. 196, N 4. P. 1069–1075. doi: 10.1016/j.juro.2016.04.003

[189] Delongchamps NB, Portalez D, Bruguière E, et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer. J Urol. 2016;196(4):1069–1075. doi: 10.1016/j.juro.2016.04.003

[190] Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122(6):884–892. doi: 10.1002/cncr.29874

[191] Filson C.P., Natarajan S., Margolis D.J., et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies // Cancer. 2016. Vol. 122, N 6. P. 884–892. doi: 10.1002/cncr.29874

[192] Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122(6):884–892. doi: 10.1002/cncr.29874

[193] Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196(6):1613–1618. doi: 10.1016/j.juro.2016.06.079

[194] Rosenkrantz A.B., Verma S., Choyke P., et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR // J Urol. 2016. Vol. 196, N 6. P. 1613–1618. doi: 10.1016/j.juro.2016.06.079

[195] Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196(6):1613–1618. doi: 10.1016/j.juro.2016.06.079

[196] Simmons LAM, Kanthabalan A, Arya M, et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017;116(9):1159–1165. doi: 10.1038/bjc.2017.57

[197] Simmons L.A.M., Kanthabalan A., Arya M., et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy // Br J Cancer. 2017. Vol. 116, N 9. P. 1159–1165. doi: 10.1038/bjc.2017.57

[198] Simmons LAM, Kanthabalan A, Arya M, et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017;116(9):1159–1165. doi: 10.1038/bjc.2017.57

[199] Hansen NL, Kesch C, Barrett T, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017;120(5):631–638. doi: 10.1111/bju.13711

[200] Hansen N.L., Kesch C., Barrett T., et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy // BJU Int. 2017. Vol. 120, N 5. P. 631–638. doi: 10.1111/bju.13711

[201] Hansen NL, Kesch C, Barrett T, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017;120(5):631–638. doi: 10.1111/bju.13711

[202] Radtke JP, Kuru TH, Bonekamp D, et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis. 2016;19(3):283–291. doi: 10.1038/pcan.2016.16

[203] Radtke J.P., Kuru T.H., Bonekamp D., et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance // Prostate Cancer Prostatic Dis. 2016. Vol. 19, N 3. P. 283–291. doi: 10.1038/pcan.2016.16

[204] Radtke JP, Kuru TH, Bonekamp D, et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis. 2016;19(3):283–291. doi: 10.1038/pcan.2016.16

[205] Henderson DR, de Souza NM, Thomas K, et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. Eur Urol. 2016;69(6):1028–1033. doi: 10.1016/j.eururo.2015.10.010

[206] Henderson D.R., de Souza N.M., Thomas K., et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort // Eur Urol. 2016. Vol. 69, N 6. P. 1028–1033. doi: 10.1016/j.eururo.2015.10.010

[207] Henderson DR, de Souza NM, Thomas K, et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. Eur Urol. 2016;69(6):1028–1033. doi: 10.1016/j.eururo.2015.10.010

[208] Frye TP, George AK, Kilchevsky A, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol. 2017;197(3 Pt 1):640–646. doi: 10.1016/j.juro.2016.08.109

[209] Frye T.P., George A.K., Kilchevsky A., et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer // J Urol. 2017. Vol. 197, N 3 Pt 1. P. 640–646. doi: 10.1016/j.juro.2016.08.109

[210] Frye TP, George AK, Kilchevsky A, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol. 2017;197(3 Pt 1):640–646. doi: 10.1016/j.juro.2016.08.109

[211] Recabal P, Assel M, Sjoberg DD, et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. J Urol. 2016;196(2):374–381. doi: 10.1016/j.juro.2016.02.084

[212] Recabal P., Assel M., Sjoberg D.D., et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance // J Urol. 2016. Vol. 196, N 2. P. 374–381. doi: 10.1016/j.juro.2016.02.084

[213] Recabal P, Assel M, Sjoberg DD, et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. J Urol. 2016;196(2):374–381. doi: 10.1016/j.juro.2016.02.084

[214] Tran GN, Leapman MS, Nguyen HG, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017;72(2):275–281. doi: 10.1016/j.eururo.2016.08.023

[215] Tran G.N., Leapman M.S., Nguyen H.G., et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance // Eur Urol. 2017. Vol. 72, N 2. P. 275–281. doi: 10.1016/j.eururo.2016.08.023

[216] Tran GN, Leapman MS, Nguyen HG, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017;72(2):275–281. doi: 10.1016/j.eururo.2016.08.023

RIGHTS & PERMISSIONS

Eco-Vector